Bio­phar­ma ven­ture fund­ing falls to the low­est to­tal since 2019 as star­tups pon­der al­ter­na­tive paths

Ven­ture cap­i­tal in­vest­ments in biotech and phar­ma hit a more than three-year low last quar­ter as a pro­longed mar­ket down­turn forced dif­fi­cult next-step de­ci­sions for star­tups and in­vestors.

In the first quar­ter, VCs in­vest­ed just $4.1 bil­lion in­to biotech and phar­ma com­pa­nies, the low­est quar­ter­ly to­tal since the end of 2019 when they put in $4.0 bil­lion, ac­cord­ing to da­ta from Pitch­Book, which tracks deals. There were few­er in­vest­ments as well — 203 in the first quar­ter, the small­est count since 2016.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER